Latest News & Updates
Stay Ahead in a Defining Year for Biosimilars and Biologics
Join ACI’s Biosimilars & Innovator Biologics Summit in New York and connect with industry leaders navigating the biggest shifts in IP, regulation, and market access.
Get practical insights on:
- Evolving IP and litigation strategies
- FDA and regulatory developments
- Market access and pricing pressures
- Global competition shaping the future of biologics
2026 will define the next phase of innovation and patient access. Join the “who’s who” of the biosimilars and innovator biologics community this June in New York and make sure you’re part of the conversation.
View Agenda
Conference Co-Chairs
James Evans
Senior Director, Assistant General Counsel, Global IP Litigation
Regeneron Pharmaceuticals, Inc.
Katie Nolan-Stevaux
Head of General Litigation, Associate General Counsel
Genentech
Jason Murata
Vice President, Intellectual Property
Alvotech
Government Speakers
Mustafa Ünlü
Policy Staff Director, Office of Therapeutic Biologics and Biosimilars
U.S. Food and Drug Administration
Anu Sawkar
Special Counsel for Intellectual Property
Federal Trade Commission
View All Speakers
Advisory Board
ACI’s Biosimilars & Innovator Biologics Advisory Board ensures our programs deliver cutting-edge insights with a world-class faculty. Composed of senior IP, market access, regulatory, and policy leaders from both biosimilar and innovator biologics companies, the board provides strategic guidance on litigation, competition, and evolving market dynamics. Balancing perspectives across the industry, this inner circle helps shape critical discussions on innovation, access, and the future of biologics.
Core Topics Shaping the Conversation
Skinny Labeling and Induced-Infringement may reshape litigation strategy and marketing practices across the industry
The parameters of the Safe Harbor Defense to Patent Infringement are evolving
The price control provisions of the IRA continue to influence innovator biologic and biosimilar development
Artificial Intelligence and IP Strategies can alter product development and litigation planning
Earn CLE/Ethics Credits
Accreditation will be sought in those jurisdictions requested by the registrants which have continuing education requirements. This course is identified as non-transitional for the purposes of CLE accreditation.
Learn more
Join Our Companion Event
GLP-1 Law & Policy
June 4, 2026 • 3 Times Square, New York, NY
Join industry leaders in-person in New York City for this timely event that will cover everything from advertising to mass torts to peptides.
Sponsors & Partners
Supporting Sponsors
Associate Sponsors
Media Partners
Sponsor Opportunities
With conferences in the United States, Europe, Asia Pacific, and Latin America, the C5 Group of Companies: American Conference Institute, the Canadian Institute, and C5 Group, provides a diverse portfolio of conferences, events and roundtables devoted to providing business intelligence to senior decision makers responding to challenges around the world.
For more information please contact:
Aaron Goldstein
Senior Business Development Manager
Email: [email protected]